International Assets Investment Management LLC Makes New $47,000 Investment in TransMedics Group, Inc. (NASDAQ:TMDX)

International Assets Investment Management LLC purchased a new stake in TransMedics Group, Inc. (NASDAQ:TMDX) during the second quarter, according to the company in its most recent disclosure with the SEC. The firm purchased 310 shares of the company’s stock, valued at approximately $47,000.

Several other hedge funds and other institutional investors have also made changes to their positions in the stock. J.Safra Asset Management Corp raised its holdings in TransMedics Group by 649.2% in the second quarter. J.Safra Asset Management Corp now owns 442 shares of the company’s stock valued at $67,000 after acquiring an additional 383 shares in the last quarter. Signaturefd LLC increased its position in shares of TransMedics Group by 26.6% in the 2nd quarter. Signaturefd LLC now owns 443 shares of the company’s stock valued at $67,000 after purchasing an additional 93 shares during the last quarter. Fidelis Capital Partners LLC acquired a new stake in shares of TransMedics Group in the 1st quarter valued at $35,000. HB Wealth Management LLC purchased a new stake in shares of TransMedics Group during the 2nd quarter worth $318,000. Finally, Yarbrough Capital LLC acquired a new position in shares of TransMedics Group during the second quarter worth $383,000. Hedge funds and other institutional investors own 99.67% of the company’s stock.

TransMedics Group Stock Performance

Shares of TransMedics Group stock opened at $143.39 on Friday. The firm’s fifty day simple moving average is $155.04 and its 200-day simple moving average is $123.98. TransMedics Group, Inc. has a 12 month low of $36.42 and a 12 month high of $177.37. The stock has a market capitalization of $4.72 billion, a price-to-earnings ratio of -421.72 and a beta of 1.99. The company has a debt-to-equity ratio of 2.67, a current ratio of 9.37 and a quick ratio of 8.48.

TransMedics Group (NASDAQ:TMDX) last announced its earnings results on Wednesday, July 31st. The company reported $0.35 EPS for the quarter, beating analysts’ consensus estimates of $0.21 by $0.14. TransMedics Group had a net margin of 0.84% and a return on equity of 15.98%. The business had revenue of $114.30 million during the quarter, compared to analysts’ expectations of $98.84 million. During the same period in the prior year, the company earned ($0.03) earnings per share. The business’s revenue was up 117.7% compared to the same quarter last year. As a group, equities analysts forecast that TransMedics Group, Inc. will post 1.2 earnings per share for the current year.

Analyst Upgrades and Downgrades

A number of research firms have weighed in on TMDX. Canaccord Genuity Group raised their price target on TransMedics Group from $117.00 to $169.00 and gave the company a “buy” rating in a research note on Thursday, August 1st. Oppenheimer upped their price target on TransMedics Group from $125.00 to $200.00 and gave the company an “outperform” rating in a report on Thursday, August 1st. TD Cowen increased their price target on shares of TransMedics Group from $130.00 to $175.00 and gave the company a “buy” rating in a research note on Friday, June 7th. Needham & Company LLC assumed coverage on shares of TransMedics Group in a report on Wednesday, August 21st. They issued a “buy” rating and a $208.00 target price for the company. Finally, Morgan Stanley increased their target price on shares of TransMedics Group from $104.00 to $145.00 and gave the company an “equal weight” rating in a research report on Monday, July 15th. One analyst has rated the stock with a hold rating and eight have assigned a buy rating to the company. According to data from MarketBeat, the company has an average rating of “Moderate Buy” and an average price target of $171.44.

Insiders Place Their Bets

In other news, Director James R. Tobin sold 20,000 shares of the business’s stock in a transaction that occurred on Thursday, August 8th. The stock was sold at an average price of $159.33, for a total value of $3,186,600.00. Following the transaction, the director now owns 173,146 shares of the company’s stock, valued at $27,587,352.18. The transaction was disclosed in a filing with the SEC, which is available at the SEC website. In related news, insider Tamer I. Khayal sold 2,958 shares of the firm’s stock in a transaction dated Thursday, August 1st. The shares were sold at an average price of $156.77, for a total value of $463,725.66. Following the completion of the sale, the insider now owns 20,843 shares in the company, valued at $3,267,557.11. The sale was disclosed in a legal filing with the SEC, which is available through the SEC website. Also, Director James R. Tobin sold 20,000 shares of TransMedics Group stock in a transaction that occurred on Thursday, August 8th. The shares were sold at an average price of $159.33, for a total value of $3,186,600.00. Following the completion of the sale, the director now directly owns 173,146 shares in the company, valued at approximately $27,587,352.18. The disclosure for this sale can be found here. In the last ninety days, insiders sold 61,247 shares of company stock valued at $9,551,089. 7.00% of the stock is owned by company insiders.

About TransMedics Group

TransMedics Group, Inc, a commercial-stage medical technology company, engages in transforming organ transplant therapy for end-stage organ failure patients in the United States and internationally. The company offers Organ Care System (OCS), a portable organ perfusion, optimization, and monitoring system that utilizes its proprietary and customized technology to replicate near-physiologic conditions for donor organs outside of the human body.